Yadav MP - Search Results

1

Head-to-head comparison of [⁶⁸Ga]Ga-DOTA.SA.FAPi with [¹⁸F]F-FDG PET/CT in radioiodine-resistant follicular-cell derived thyroid cancers.

Ballal S, Yadav MP, Roesch F, Satapathy S, Moon ES, Martin M, Wakade N, Sheokand P, Tripathi M, Chandekar KR, Agarwal S, Sahoo RK, Rastogi S, Bal C. Ballal S, et al. Among authors: yadav mp. Eur J Nucl Med Mol Imaging. 2023 Dec;51(1):233-244. doi: 10.1007/s00259-023-06404-z. Epub 2023 Aug 29. Eur J Nucl Med Mol Imaging. 2023. PMID: 37642703

2

An approach for conjugation of (177) Lu- DOTA-SCN- Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients.

Thakral P, Singla S, Yadav MP, Vasisht A, Sharma A, Gupta SK, Bal CS; Snehlata; Malhotra A. Thakral P, et al. Among authors: yadav mp. Indian J Med Res. 2014 Apr;139(4):544-54. Indian J Med Res. 2014. PMID: 24927340 Free PMC article.

3

Dosimetric analysis of 177Lu-DOTA-rituximab in patients with relapsed/refractory non-Hodgkin's lymphoma.

Yadav MP, Singla S, Thakral P, Ballal S, Bal C. Yadav MP, et al. Nucl Med Commun. 2016 Jul;37(7):735-42. doi: 10.1097/MNM.0000000000000501. Nucl Med Commun. 2016. PMID: 26974315 Clinical Trial.

4

Cocktail Therapy of 177Lu-PSMA-617 and 177Lu-EDTMP in Patients With mCRPC: A Proof-of-Principle Application.

Bal C, Yadav MP, Ballal S. Bal C, et al. Among authors: yadav mp. Clin Nucl Med. 2016 Aug;41(8):e386-7. doi: 10.1097/RLU.0000000000001251. Clin Nucl Med. 2016. PMID: 27187728

5

Evaluation of bone-seeking novel radiotracer ⁶⁸Ga-NO2AP-Bisphosphonate for the detection of skeletal metastases in carcinoma breast.

Passah A, Tripathi M, Ballal S, Yadav MP, Kumar R, Roesch F, Meckel M, Sarathi Chakraborty P, Bal C. Passah A, et al. Among authors: yadav mp. Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):41-49. doi: 10.1007/s00259-016-3469-3. Epub 2016 Jul 25. Eur J Nucl Med Mol Imaging. 2017. PMID: 27455986

6

¹⁷⁷Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment.

Yadav MP, Ballal S, Tripathi M, Damle NA, Sahoo RK, Seth A, Bal C. Yadav MP, et al. Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):81-91. doi: 10.1007/s00259-016-3481-7. Epub 2016 Aug 10. Eur J Nucl Med Mol Imaging. 2017. PMID: 27506431 Clinical Trial.

7

Reply to Rahbar K et al.

Yadav MP, Ballal S, Tripathi M, Bal C. Yadav MP, et al. Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):168-169. doi: 10.1007/s00259-016-3531-1. Epub 2016 Oct 1. Eur J Nucl Med Mol Imaging. 2017. PMID: 27695908 No abstract available.

8

Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer.

Yadav MP, Ballal S, Tripathi M, Damle NA, Sahoo RK, Seth A, Bal C. Yadav MP, et al. Nucl Med Commun. 2017 Jan;38(1):91-98. doi: 10.1097/MNM.0000000000000606. Nucl Med Commun. 2017. PMID: 27782913

9

Estimation of Whole Body Radiation Exposure to Nuclear Medicine Personnel During Synthesis of ¹⁷⁷Lutetium-labeled Radiopharmaceuticals.

Arora G, Mishra R, Kumar P, Yadav M, Ballal S, Bal C, Damle NA. Arora G, et al. Indian J Nucl Med. 2017 Apr-Jun;32(2):89-92. doi: 10.4103/0972-3919.202245. Indian J Nucl Med. 2017. PMID: 28533634 Free PMC article.

10

Concomitant 177Lu-DOTATATE and Capecitabine Therapy in Patients With Advanced Neuroendocrine Tumors: A Long-term-Outcome, Toxicity, Survival, and Quality-of-Life Study.

Ballal S, Yadav MP, Damle NA, Sahoo RK, Bal C. Ballal S, et al. Among authors: yadav mp. Clin Nucl Med. 2017 Nov;42(11):e457-e466. doi: 10.1097/RLU.0000000000001816. Clin Nucl Med. 2017. PMID: 28872545

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

146 results

Search Page